Biotech Press Releases

Competitive National Eye Institute funding provides external validation of ClearSight's proposed scientific program and supports a one-year investigation of a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic...

Independent private autopsies are playing an increasingly critical role in civil litigation.

New worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's platform, creating a potential path from patient subtypes and biomarkers to biological mechanisms and therapeutic targets.

OriginBio has published a technical guide examining the role of liposomal delivery in functional nutrition. The guide explains how phospholipid vesicles are designed, processed and evaluated for use in supplement formulation.

A3 Analytics, the AI-native operational intelligence company for automated and self-driving laboratories, today announced that Greg Snyder, PhD, has joined the company as Co-Founder and Chief Operating Officer.

With $NTRB shares gaining significant momentum in September, investors are watching a rapidly approaching warrant expiration, new intellectual-property progress for Nutriband's abuse-deterrent fentanyl platform, strengthening visibility through Nasdaq's..

SignaBlok, Inc. has been awarded a Phase I SBIR grant from the NIH NIDDK to advance the development of a novel mechanism-based therapy for inflammatory bowel disease (IBD). The award supports SignaBlok's differentiated approach to targeting TREM-1 in IBD.

With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts

Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to...

NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026...

With revenue shifting rapidly beyond China, positive net income returning, new international registrations, an expanding U.S.

New NIH funding advances Oak's proprietary high-drug-load ODS platform toward scalable manufacturing

Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.

Nomination recognizes synseer's mission to transform the ear into a continuous health-intelligence platform helping people understand, manage and extend their healthspan.

First-cycle FDA review delivers one of the strongest signals yet that NRx's preservative-free ketamine opportunity may be entering its final stretch, while the company's broader neuropsychiatric pipeline continues to gain momentum.

Boston Industrial Solutions announces the launch of SAP-G70 Silicone Primer, designed for effective bonding of silicone to silicone and various other materials.

Potential DARPA Award, FDA-Authorized Phase 2/3 Trial, Breakthrough Therapy NRX-101, and Robotic-Enabled TMS Platform Highlight Expanding Opportunities for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)

Advanced formulation technologies, fastest-growing health categories and premium supplement manufacturing solutions

Slimshot® recognized in Medical Devices & Technology Concept category; product selected for display at Red Dot Design Museum in Singapore.

Natural Field, a nutraceutical ingredient manufacturer specializing in innovative delivery systems, unveiled NF TriSolve® at CPHI China 2026, showcasing its latest advancement in science-driven nutritional formulation solutions.

Competitive National Eye Institute funding provides external validation of ClearSight's proposed scientific program and supports a one-year investigation of a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic...

Independent private autopsies are playing an increasingly critical role in civil litigation.

New worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's platform, creating a potential path from patient subtypes and biomarkers to biological mechanisms and therapeutic targets.

Independent analysis puts Base fair value near $63 per share against a $104.71 reference price, with 6,000 prevalent patient starts reaching only ~$91.

OriginBio has published a technical guide examining the role of liposomal delivery in functional nutrition. The guide explains how phospholipid vesicles are designed, processed and evaluated for use in supplement formulation.

A3 Analytics, the AI-native operational intelligence company for automated and self-driving laboratories, today announced that Greg Snyder, PhD, has joined the company as Co-Founder and Chief Operating Officer.

With $NTRB shares gaining significant momentum in September, investors are watching a rapidly approaching warrant expiration, new intellectual-property progress for Nutriband's abuse-deterrent fentanyl platform, strengthening visibility through Nasdaq's..

Artificial Organs Market is projected to expand from USD 28.71 billion in 2025 to USD 63.31 billion by 2035, driven by rising organ failure, implantable technologies, advanced biomaterials, bioengineering and 3D bioprinting.

SignaBlok, Inc. has been awarded a Phase I SBIR grant from the NIH NIDDK to advance the development of a novel mechanism-based therapy for inflammatory bowel disease (IBD). The award supports SignaBlok's differentiated approach to targeting TREM-1 in IBD.

Published COAs, single vials and research kits, multiple payment options, and domestic U.S. shipping give buyers practical ways to compare suppliers.

With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts

Dr.Pati Abhay Kumar  USA Profile : https://www.Patikumar.com Real Story of Ayurveda & AYURVEDIC SCIENCE & Medicine Medicine means art of healing Medicine does not mean Emergency Chemically synthesized pharma drug at all.

Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to...

Independent simulation estimates ~19% probability of null Lp(a) biology and reduces OCEAN(a)'s modeled statistical-success probability from 87.9% to ~65–72%

NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026...

With revenue shifting rapidly beyond China, positive net income returning, new international registrations, an expanding U.S.

Creative Biolabs is highlighting a species-aware workflow that connects target strategy, veterinary therapeutic antibody discovery, engineering, characterization, and downstream candidate assessment.

AYURVEDA TODAY Ayurvedic Plants based ingredients: Dr.Abhay Kumar Pati, Physician, Author, Researcher, Industry Specialist on natural ingredients.

Generative AI in Healthcare Market Executive Summary, Segmentation, Review, Trends, Opportunities, Growth, Demand and Forecast to 2031

New NIH funding advances Oak's proprietary high-drug-load ODS platform toward scalable manufacturing

Neurogut Inc. is proud to announce the granting of US Patent US12575788B2 for its Bioanatoner device, a groundbreaking biofeedback system designed to transform the treatment of anorectal and pelvic floor disorders.

Independent analysis finds Zenkuda more likely than not to achieve non-inferiority, while the quality of vision preservation and achieved dosing durability could produce materially different commercial and valuation outcomes.

MARKET OVERVIEW: Precision fermentation is moving beyond alternative dairy into collagen, nutraceuticals, functional nutrition and specialty ingredients.

Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.

Metavalis Inc. details advanced R&D across genomic radioprotection, neural interfacing, and cryopreservation, powered by the A.L.I.C.E. computational platform.

Independent analysis finds Phase 3 statistical success increasingly de-risked, while complete-response differentiation, replicate-trial consistency and KIT-related safety remain the key determinants of valuation.

Frontier in Immunology a dendritic instruction for anti aging , cancer and autoimmune

Nomination recognizes synseer's mission to transform the ear into a continuous health-intelligence platform helping people understand, manage and extend their healthspan.

Community mixer, "Ask the Doctor" session, documentary preview, and family giveaways headline the second stop in NOWINCLUDED'S Clear the Air series

Independent analysis finds ulixacaltamide approval increasingly likely, while identifying residual FDA uncertainty and post-approval commercial persistence as underappreciated risks.

The strategic capital injection will scale biological payloads and expand the V18 Prometheus neural topology of the world's most powerful AI, A.L.I.C.E.